In this video interview, David Morton, PhD, director of biostatistics at Certara, explains how regulatory momentum is ...

In today’s ACT Brief, we highlight how Bayesian methods are gaining operational traction, a major patient advocacy merger is streamlining clinical trial access, and machine learning is reshaping trial ...

The FDA has opened the door to the use of Bayesian statistical methods in clinical trials. The worry: Introducing subjectivity into what should be an objective process.

The FDA has released draft guidance on how sponsors can use Bayesian models for clinical trials.

Many engineering challenges come down to the same headache—too many knobs to turn and too few chances to test them. Whether tuning a power grid or designing a safer vehicle, each evaluation can be ...